Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Next Generation Drug Conjugates Market Trends and Global Forecasts, 2025-2035 - Lutathera, Pluvicto, Givlaari, Oxlumo, Leqvio, and Amvuttra Represent Milestones in Advanced Treatment Solutions - ResearchAndMarkets.com

businesswire.com
NVS Mentioned as a key market player in the growing next-generation drug conjugates market, indicating its involvement in a promising sector. ALNY Identified as a key market player in the expanding next-generation drug conjugates sector, suggesting potential growth and relevance. ARWR Listed as a key participant in the growing next-generation drug conjugates market, indicating its role in an advancing therapeutic area. GERN Included as a key market player in the projected growth of the next-generation drug conjugates market. IONS Cited as a key market player in the expanding next-generation drug conjugates market, indicating its presence in a developing therapeutic field.

DUBLIN--( BUSINESS WIRE)--The "Next Generation Drug Conjugates Market: Industry Trends and Global Forecasts, Till 2035" has been added to ResearchAndMarkets.com's offering.

The global next-generation drug conjugates market is projected to surge from USD 4.2 billion in the current year to USD 15.5 billion by 2035, displaying a CAGR of 14.0% during the forecast period.

Next-generation drug conjugates are emerging as significant targeted treatments, particularly for rare diseases and various cancers, due to their non-immunogenicity, structural reliability, and effectiveness in precise delivery with minimized side effects. These conjugates utilize a diverse array of targeting agents and payloads, demonstrating efficacy against solid tumors, metabolic disorders, and hematological conditions.

Recent USFDA approvals for six next-generation drug conjugates underscore their clinical promise. Lutathera, Pluvicto, Givlaari, Oxlumo, Leqvio, and Amvuttra represent milestones in advanced treatment solutions. Market growth is expected due to ongoing innovations, successful trials, and strategic partnerships.

NEXT GENERATION DRUG CONJUGATES MARKET: KEY SEGMENTS

Currently, ligand-mediated RNAi conjugates lead the market. However, future growth is anticipated in ligand-attached anti-sense therapies. In terms of targeting ligand types, peptides currently hold a significant market share, yet amino sugars are projected to dominate in the upcoming decade.

Radionuclides are the leading payloads, with Si-RNA conjugates expected to expand quickly. Combination therapies also dominate, particularly through the intravenous route, though subcutaneous delivery is poised for significant growth.

Targeted indications like prostate cancer dominate the market share, while the hemophilia segment is set to grow rapidly.

MARKET GEOGRAPHY AND PARTICIPANTS

North America currently captures the largest market share, with notable growth anticipated in Asia-Pacific and other global regions. Key market players include Advanced Accelerator Applications (Novartis), Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Geron Corporation, and Ionis Pharmaceuticals.

NEXT GENERATION DRUG CONJUGATES MARKET: KEY INSIGHTS

RESEARCH COVERAGE

KEY QUESTIONS ANSWERED

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

Key Attributes:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/7fusw1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.